Clinical Trial: NCT07307911
Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Damanhour University |
| Information Provided By: | Damanhour University |
| Last Update Posted: | 2026-04-08 |
Study Overview
Brief Summary
- This study aims to investigate whether Coenzyme Q10 supplementation can reduce chemotherapy-induced peripheral neuropathy, fatigue, and pain in women with newly diagnosed breast cancer receiving paclitaxel treatment. The study will also examine the effects of Coenzyme Q10 on biomarkers associated with nerve damage. The main questions it seeks to answer are:
- Does Coenzyme Q10 improve patients' quality of life by reducing neuropathy, fatigue, and pain during chemotherapy?
- How does Coenzyme Q10 affect serum levels of nerve growth factor, neurofilament light chain, malondialdehyde, and osteopontin during treatment?
- Participants will: Receive either Coenzyme Q10 along with standard weekly paclitaxel chemotherapy or paclitaxel alone for twelve weeks.
- Complete questionnaires on neuropathy, fatigue, and pain at the end of each chemotherapy cycle.
- Provide blood samples at the beginning and end of the study to measure biomarkers of nerve injury.
Official Title
Neuroprotective Effects of Coenzyme Q10 in Paclitaxel-Induced Peripheral Neuropathy
Conditions
Breast Cancer
Intervention / Treatment
- Dietary Supplement: Coenzyme Q 10
- Drug: Paclitaxel
Other Study ID Numbers
- CoQ10-PN-2025-01
Start Date (Actual)
2025-11-10
Primary Completion Date (Actual)
2026-02-10
Study Completion Date (Actual)
2026-02-10
Enrollment (Actual)
50
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Damanhour University |
| Information Provided By: | Damanhour University |
| Last Update Posted: | 2026-04-08 |
Study Overview
Brief Summary
- This study aims to investigate whether Coenzyme Q10 supplementation can reduce chemotherapy-induced peripheral neuropathy, fatigue, and pain in women with newly diagnosed breast cancer receiving paclitaxel treatment. The study will also examine the effects of Coenzyme Q10 on biomarkers associated with nerve damage. The main questions it seeks to answer are:
- Does Coenzyme Q10 improve patients' quality of life by reducing neuropathy, fatigue, and pain during chemotherapy?
- How does Coenzyme Q10 affect serum levels of nerve growth factor, neurofilament light chain, malondialdehyde, and osteopontin during treatment?
- Participants will: Receive either Coenzyme Q10 along with standard weekly paclitaxel chemotherapy or paclitaxel alone for twelve weeks.
- Complete questionnaires on neuropathy, fatigue, and pain at the end of each chemotherapy cycle.
- Provide blood samples at the beginning and end of the study to measure biomarkers of nerve injury.
Official Title
Neuroprotective Effects of Coenzyme Q10 in Paclitaxel-Induced Peripheral Neuropathy
Conditions
Breast Cancer
Intervention / Treatment
- Dietary Supplement: Coenzyme Q 10
- Drug: Paclitaxel
Other Study ID Numbers
- CoQ10-PN-2025-01
Start Date (Actual)
2025-11-10
Primary Completion Date (Actual)
2026-02-10
Study Completion Date (Actual)
2026-02-10
Enrollment (Actual)
50
Study Type
Interventional
Phase
Phase 2